IndraLab

Statements

HDAC_I inhibits BAP1. 2 / 2
| 2
reach
"Histone deacetylase (HDAC) inhibitors, such as the readily available valproic acid, can reverse this effect of BAP1 loss and may play a role in treated patients with high-risk class 2 uveal melanomas in an adjuvant setting prior to the emergence of overt metastatic disease [XREF_BIBR]."
24713608
reach
"Histone deacetylase (HDAC) inhibitors have been shown to reverse the phenotypic effects of BAP1 loss by inducing morphologic differentiation and transition from a high-risk to a low-risk gene expression profile in uveal melanoma cells."
29497459